Developed in TEDA! China’s First Three-Component Pertussis-Containing Vaccine Approved for Marketing

Recently, the infant-use adsorbed acellular pertussis (three-component), diphtheria, and tetanus combined vaccine, Pankangxin®, independently developed by CanSino Biologics Inc., received approval from China’s National Medical Products Administration. As the first approved component pertussis-containing vaccine in China, Pankangxin® not only contains PT antigen and FHA antigen but also includes the key antigen PRN, offering more comprehensive protection. Moreover, the vaccine is free from thimerosal, antibiotics, and animal-derived ingredients, resulting in a purer composition and a more than 50% reduction in the incidence of fever following booster immunization.

Founded in TEDA in 2009, CanSino Biologics Inc. focuses on the R&D, production, and commercialization of innovative, high-quality, and accessible human vaccines. The leading high-tech biopharmaceutical enterprise has established five major technology platform, namely viral vector vaccine technology, synthetic vaccine technology, protein structure design and VLP assembly technology, mRNA vaccine technology, and formulation and delivery technology. It also developed a highly competitive product pipeline.